China Resources Pharmaceutical Group Ltd. hat am 6. Februar 2026 eine außerordentliche Hauptversammlung abgehalten. Die vorgeschlagenen Punkte – die Genehmigung fortlaufender verbundener Transaktionen im Rahmen des Sales Framework Agreement 2026/2028 sowie die Änderungen der Satzung – wurden jeweils angenommen.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018532), on February 06, 2026, and is solely responsible for the information contained therein.